Montreal, Quebec, Canada (Signal High) —– A multi-million dollar, class action lawsuit against the maker of drug Rexulti (brexpaprasole), has been settled for $4.75MM (CAD). The class action involved persons in Canada prescribed the drug after February 16, 2017, who experienced compulsive behaviours or impulse-control disorders, e.g. compulsive gambling, hyper sexuality, compulsive spending, binge-eating, etc.
According to WebMD, “Rexulti (brexpiprazole) is commonly used to treat people with depression, schizophrenia, or agitation due to dementia with Alzheimer’s disease.”
+10,427+
Notice – Fair Use. This article may use copyrighted material in a manner that does not require approval of the copyright holder (i.e. journalism, critique, reporting of news). It is fair use under copyright law. Pursuant to section 107 of the Copyright Act of 1976, “the fair use of a copyrighted work […] for purposes such as criticism, comment, news reporting, teaching (including multiple copies for classroom use), scholarship, or research, is not an infringement of copyright.” – 17 U.S. Code § 107.
